NCT01110746View on ClinicalTrials.gov

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Viaject 7

100IU/mL administered subcutaneously

DRUG

LISPRO

100IU/mL administered subcutaneously

Trial Locations (1)

97232

Oregon Health and Science University/Legacy Health System, Portland

Sponsors

Lead Sponsor

Biodel
All Listed Sponsors
lead

Biodel

INDUSTRY